RAMSEY, NJ & BOCA RATON, Fla., December 9, 2022 (GLOBE NEWSWIRE) — ADMA Biologics, Inc. (Nasdaq:ADMA) (“ADMA” or the “Company”) is an end-to-end commercial biopharmaceutical company . The company, dedicated to the manufacturing, marketing and development of specialty plasma-derived biologics, today announced the closing of its previously announced underwritten public offering of 20,979,020 shares of common stock at an offering price of $2.86 per share. Underwriter’s option to purchase an additional 3,146,853 shares of common stock. Total proceeds from the exercise of the over-allotment option were $9 million, which, before deducting underwriting discounts and fees and other estimated offering costs, brought total proceeds to ADMA from the offering of $69 million.
ADMA will use the net proceeds from this offering to accelerate commercialization and production activities, complete the construction of a plasma center, obtain FDA approval, complete research and development projects after FDA marketing approval, and to fund working capital, capital expenditures, and general investment. intended to be used for commercial purposes.
Raymond James & Associates, Inc., Cantor Fitzgerald & Co. and Mizuho Securities USA LLC acted as joint bookrunners for the offering.
The above offering of securities is on Form S-3 (File No. 333-256643) previously filed with the U.S. Securities and Exchange Commission (“SEC”) and declared effective by the U.S. Securities and Exchange Commission (“SEC”). Shelves” was made by us in accordance with the registration statement. Filed with the SEC on August 3, 2021. A definitive prospectus supplement relating to the offering, including an accompanying prospectus, will be filed with the SEC on December 7, 2022 and will be available on the SEC’s website at www.sec.gov. An electronic copy of the definitive prospectus for offering and an accompanying prospectus may be obtained from Raymond James & Associates, Inc., Attention: Equity Syndicate, 880 Carillon Parkway, St. Petersburg, Florida 33716 or by calling (800). increase. 248-8863, email to email@example.com, or from Cantor Fitzgerald & Co., Capital Markets, 499 Park Avenue, 4th Floor, New York, New York 10022 or email firstname.lastname@example.org, or Mizuho Securities USA LLC, Attention: Equity Capital Markets, 1271 Avenue of the Americas, 3rd Floor, New York, NY 10020 by email (US-ECM@us.mizuho-sc.com) or by phone (212) 205-7600.
This press release does not constitute an offer to sell or the solicitation of an offer to buy any securities described herein, and such offer, solicitation or sale is unlawful in any state or jurisdiction. It is not intended to sell securities. Registration or qualification under the securities laws of such state or jurisdiction.
About ADMA Biologics, Inc. (ADMA)
ADMA Biologics is an end-to-end commercial company dedicated to the manufacture, marketing and development of specialty plasma-derived biologics to treat immunocompromised patients at risk for infection and other patients at risk for certain infectious diseases. A biopharmaceutical company. ADMA currently manufactures and markets his three U.S. Food and Drug Administration (FDA)-approved plasma-derived biologics for the treatment of immunodeficiencies and the prevention of certain infections.® For the treatment of primary humoral immunodeficiency (PI) (intravenous immunoglobulin, human); ASCENIV™ (intravenous immunoglobulin, human – slra 10% liquid) for the treatment of PI; Navi HB® (Hepatitis B immunoglobulin, human) Provides enhanced immunity against the hepatitis B virus. ADMA manufactures its immunoglobulin products at its FDA-approved plasma fractionation and purification facility in Boca Raton, Florida. Through its subsidiary ADMA BioCenters, ADMA also operates as an FDA-approved source plasma collector in the United States, providing a portion of the plasma for the manufacture of its products. ADMA’s mission is to develop specialized plasma products targeted at niche patient populations for the treatment and prevention of specific infectious diseases and for the management of immunocompromised patient populations suffering from or potentially immunocompromised. to manufacture, market and develop human immunoglobulins derived from Weakened immunity for other medical reasons. ADMA holds U.S. Patents 9,107,906, 9,714,283, 9,815,886, 9,969,793, 10,259,865, and European Patent No. 3375789, among others, relating to certain aspects of its products and product candidates. For more information, please visit www.admabiologics.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995 relating to ADMA Biologics, Inc. (the “Company”, “Our” or “Company”). increase. Forward-looking statements include, but are not limited to, statements that may predict, predict, suggest or imply future results, performance or achievements. “goal”, “expect”, “plan”, “plan”, “expect”, “believe”, “will”, “likely”, “likely”, “all ought”, “could”, “would”, “might”, or in each case the negation thereof, or words or expressions of similar meaning. These forward-looking statements include statements regarding the intended use of the proceeds from the offering by ADMA. Actual events or results may differ materially from those described in this document due to a number of important factors. Current and future security holders are cautioned that there can be no assurance that the forward-looking statements contained in this press release will prove to be accurate. Except to the extent required by applicable law or regulation, ADMA undertakes no obligation to update any forward-looking statement or to announce revisions to any forward-looking statement. Forward-looking statements are subject to a number of risks, uncertainties and other factors that may cause actual results or the timing of certain events to be expressed or implied by the forward-looking statements. may differ significantly from risks and uncertainties described in our filings with the U.S. Securities and Exchange Commission, including our most recent reports on Forms 10-K, 10-Q, and 8-K, and any amendments thereto;
Senior Director of Corporate Strategy and Business Development | 201-478-5552 | email@example.com
Investor Relations Contact:
Managing Director, Argot Partners | 212-600-1902 | firstname.lastname@example.org